Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock Has Consensus Price Target of $65.50

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $66.75.

A number of brokerages have recently issued reports on RIGL. Cantor Fitzgerald raised their price objective on Rigel Pharmaceuticals from $43.00 to $47.00 and gave the stock a “neutral” rating in a research report on Friday, November 6th. HC Wainwright reiterated a “buy” rating and set a $85.00 price target on shares of Rigel Pharmaceuticals in a report on Monday, October 19th. Weiss Ratings lowered Rigel Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, November 9th. Piper Sandler reissued a “neutral” rating and issued a $49.00 price target (up from $40.00) on shares of Rigel Pharmaceuticals in a research note on Monday, August 17th. Finally, Zacks Research raised shares of Rigel Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday.

Read Our Latest Research Report on Rigel Pharmaceuticals

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its stake in Rigel Pharmaceuticals by 15.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,408 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 463 shares during the period. Allworth Financial LP lifted its stake in shares of Rigel Pharmaceuticals by 103.7% during the 3rd quarter. Allworth Financial LP now owns 982 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 500 shares in the last quarter. Signaturefd LLC boosted its holdings in Rigel Pharmaceuticals by 180.0% in the 3rd quarter. Signaturefd LLC now owns 826 shares of the biotechnology company’s stock worth $40,000 after buying an additional 531 shares during the period. Y Intercept Hong Kong Ltd boosted its holdings in Rigel Pharmaceuticals by 1.9% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 28,803 shares of the biotechnology company’s stock worth $779,000 after buying an additional 546 shares during the period. Finally, Signature Equity Partners LLC purchased a new position in Rigel Pharmaceuticals in the 3rd quarter valued at approximately $27,000. 66.23% of the stock is owned by institutional investors.

Rigel Pharmaceuticals Stock Performance

Shares of NASDAQ RIGL opened at $44.46 on Monday. The firm has a 50 day moving average price of $47.44 and a two-hundred day moving average price of $37.64. The stock has a market cap of $837.18 million, a P/E ratio of 2.87 and a beta of 1.28. Rigel Pharmaceuticals has a 52-week low of $24.95 and a 52-week high of $52.60.

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.27). Rigel Pharmaceuticals had a net margin of 106.59% and a return on equity of 14.89%. The company had revenue of $80.89 million during the quarter, compared to the consensus estimate of $80.00 million. Analysts predict that Rigel Pharmaceuticals will post 2.97 earnings per share for the current fiscal year.

Rigel Pharmaceuticals Company Profile

(Get Free Report)

Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation.

Featured Stories

Analyst Recommendations for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.